Date: 2013-07-29
Type of information: Grant
Company: Glycovaxyn (Switzerland)
Investors:
Amount: CHF 5.1 million (€ 4.05 million)
Funding type: award
Planned used: The award will allow GlycoVaxyn to advance its Shigella bioconjugate vaccine by funding human safety and challenge studies in healthy adults to confirm the efficacy of a monovalent Shigella flexneri 2a vaccine, before testing a multivalent vaccine in field studies in children. Clinical trials are scheduled to start in 2014 in the USA.
Others: * On July 29, 2013, GlycoVaxyn has announced that it has secured CHF 5.1 million Strategic Translation Award from the Wellcome Trust to finance clinical development of Shigella vaccine. The award will allow GlycoVaxyn to advance its Shigella bioconjugate vaccine by funding human safety and challenge studies in healthy adults to confirm the efficacy of a monovalent Shigella flexneri 2a vaccine, before testing a multivalent vaccine in field studies in children. Clinical trials are scheduled to start in 2014 in the USA.
Therapeutic area: Infectious diseases
